STAT

Tourmaline drug cuts inflammation tied to heart disease

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Business Insider

Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG

– Novartis to acquire Tourmaline Bio for $48.00 per share in cash for a total equity value of approximately $1.4 billion – – Transaction reflects the potential of Tourmaline’s pacibekitug, a ...
Wall Street Journal

Novartis Agrees to Buy Tourmaline Bio in $1.4 Billion Deal

Novartis NOVN-0.53%decrease; red down pointing triangle agreed to buy Tourmaline Bio TRML-0.04%decrease; red down pointing triangle in a roughly $1.4 billion-dollar deal that boosts its cardiovascular ...
Reuters

Novartis to acquire Tourmaline Bio for $1.4 billion

BERLIN, Sept 9 (Reuters) - Novartis (NOVN.S), opens new tab will acquire Tourmaline Bio (TRML.O), opens new tab for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion ...